Key result
DEFINITE trial evaluates whether ICDs reduce total mortality in nonischemic cardiomyopathy.
Why the study?
The efficacy of implantable cardioverter defibrillators in reducing mortality in patients with nonischemic cardiomyopathy and symptomatic heart failure with spontaneous arrhythmia was uncertain.
Does an implantable cardioverter defibrillator reduce total mortality in patients with nonischemic cardiomyopathy, symptomatic heart failure, and spontaneous arrhythmia?
RCT (n=408)
randomized
Yes
Does an implantable cardioverter defibrillator reduce total mortality in patients with nonischemic cardiomyopathy, symptomatic heart failure, and spontaneous arrhythmia?
The DEFINITE trial is designed to evaluate whether prophylactic ICD implantation reduces total mortality in patients with nonischemic cardiomyopathy, symptomatic heart failure, and spontaneous arrhythmias.
Answers are grounded in this paper and cite their sources.
ICD reduces arrhythmic death in nonischemic cardiomyopathy with LVEF ≤35%; reinforces primary-prevention ICD use while mortality benefit remains inconclusive.
The Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation (DEFINITE) is a multicenter randomized trial. Patients will have nonischemic cardiomyopathy (LVEF < or = 35%), a history of symptomatic heart failure and spontaneous arrhythmia (> 10 PVCs/hour or nonsustained ventricular tachycardia defined as 3-15 beats at a rate of > 120 beats/min) on Holter monitor or telemetry within the past 6 months. Patients will be randomized to an implantable cardioverter defibrillator (ICD) versus no ICD. All patients will receive standard oral medical therapy for heart failure including angiotensin converting enzyme inhibitors and beta-blockers (if tolerated). Patients will be followed for 2-3 years. The primary endpoint will be total mortality. Quality-of-life and pharmacoeconomics analyses will also be performed. A registry will track patients who meet basic inclusion criteria but are not randomized. We estimate an annual total mortality of 15% at 2 years in the treatment arm that does not receive an ICD. The ICD is expected to reduce mortality by 50%. Approximately 204 patients will be required in each treatment group. Twenty-five centers will be included in a trial designed to last an estimated 4 years.
No takes yet. Share an insight, caveat, or question.
Kadish et al. (2000) conducted an RCT in Nonischemic cardiomyopathy (n=408). Implantable cardioverter defibrillator (ICD) vs. No ICD was evaluated on Total mortality. The DEFINITE trial is designed to randomize approximately 408 patients to evaluate whether an implantable cardioverter defibrillator reduces total mortality in nonischemic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: